Antibody engineering is revolutionizing immuno-oncology, allowing for the synthesis of synthetic immunity by optimizing various components of antibody structure. Monoclonal antibodies (mAbs) and bispecific antibodies (BsAbs) with enhanced antibody effector functions haveRead More…
Antiretroviral therapy can suppress HIV-1 replication, but the persistence of long-lived resting memory CD4+ T cells harboring latent pre-viral HIV-1 DNA prevents a cure. To date, clinical interventions based on Latency ReversalRead More…
Immunotherapy is making significant advancements in oncology treatment. In 2021 alone, the FDA approved over a hundred monoclonal antibody drugs. Alongside monospecific antibodies, the development of multispecific antibodies is also in fullRead More…
Bispecific antibodies, with two binding sites directed at two different antigens or two different epitopes on the same antigen, have shown some superiority in clinical therapeutic effects when compared with monoclonal antibodies,Read More…
Neovascular age-related macular degeneration (nAMD ) and diabetic macular edema (DME) are retinal diseases that are the two leading causes of vision loss, affecting more than 40 million people worldwide. Roche recentlyRead More…
With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With more clinical candidates and commercial success than everRead More…
Antibody fragmentation and/or disulfide bond (DSB) reduction are common phenomena in antibody production processes, mainly caused by non-enzymatic (environmental) factors and enzymatic catalysis. Compared with traditional monoclonal antibodies (mAbs), bispecific antibodies (bsAbs)Read More…
Distinctive BsAb Platform The problem of chain mismatches will reduce the yield of the bsAb, increase the difficulty of purification, and increase the production cost. Therefore, obtaining a correctly assembled bsAb hasRead More…
Bispecific antibody (bsAb) refers to a molecule that can bind to two different antigens or to two different epitopes of the same antigen. The concept of bsAbs was first proposed by NisonoffRead More…
In the past two decades, advances in biotechnology have brought improvements in protein engineering and manufacturing technology, and promoted the development of increasingly complex bispecific antibodies (BsAbs). At present, more than 100Read More…